Acurx Pharmaceuticals EBIT

The latest EBIT for ACXP is $-2B as of June 2026. That compares with $-7.2M in the prior-year period — down 27632.0% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Acurx Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, ACXP's EBIT moved from $-7.2M to $-2B — a 27632.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Acurx Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, ACXP currently prints $-2B for EBIT, while the sector average sits near $110B. That is roughly 101.9% below the sector mean. Large gaps often invite a closer look at Acurx Pharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $-2B for ACXP is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting ACXP's EBIT ($-2B), review year-over-year change from $-7.2M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.